EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance

Ya-Chi Chen

Bioconjugate Insights · 31.03.2026 · 1 (2) · 81–85

DOI: 10.18609/bci.2026.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 31.03.2026. Verfasst von Ya-Chi Chen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“Instead of fighting tumor adaptation, we are using it to guide our design.”Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Ya-Chi Chen, Chief Scientific Officer, OBI Pharma, about the design of a bispecific, dual-payload ADC, and how this strategy aims to address tumor resistance, heterogeneity, and payload limitations in difficult-to-treat cancers.

Zitieren

APA

Chen, Y. (2026). Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance. Bioconjugate Insights, 1(2), 81–85. https://doi.org/10.18609/bci.2026.012

Vancouver

Chen Y. Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance. Bioconjugate Insights. 2026;1(2):81–85. doi:10.18609/bci.2026.012

BibTeX
@article{Chen2026,
  author = {Chen, Ya-Chi},
  title = {Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance},
  journal = {Bioconjugate Insights},
  year = {2026},
  volume = {1},
  number = {2},
  pages = {81–85},
  doi = {10.18609/bci.2026.012}
}
Kostenlos starten →